R788 as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia

Trial Profile

R788 as treatment for residual disease after chemotherapy in patients with chronic lymphocytic leukemia

Discontinued
Phase of Trial: Phase II

Latest Information Update: 30 Jun 2014

At a glance

  • Drugs Fostamatinib (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 30 Jun 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top